TScan Therapeutics
TCRX
28 hedge funds and large institutions have $69.9M invested in TScan Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.
244% more capital invested
Capital invested by funds: $20.3M → $69.9M (+$49.6M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
7.68% more ownership
Funds ownership: 51.04% → 58.72% (+7.7%)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$14M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$13.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.25M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$8.02M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$675K |
| 2 |
NM
Newtyn Management
New York
|
-$497K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$174K |
| 4 |
Morgan Stanley
New York
|
-$61.3K |
| 5 |
CC
Cannell Capital
Alta,
Wyoming
|
-$30.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACA
26
Atlas Capital Advisors
Jackson,
Wyoming
| $2.24K | – | – | – |
|
27
Bank of America
Charlotte,
North Carolina
| $500 | – | – | – |
|
28
Wells Fargo
San Francisco,
California
| $200 | +$13 | +5 | +7% |
|
|
NM
29
Newtyn Management
New York
| – | -$497K | -236,800 | Closed |
|
|
CC
30
Cannell Capital
Alta,
Wyoming
| – | -$30.8K | -14,666 | Closed |
|
31
LPL Financial
San Diego,
California
| – | -$25.2K | -12,000 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$9K | -4,147 | Closed |
|
33
Osaic Holdings
Scottsdale,
Arizona
| – | -$2 | -1 | Closed |
|
TCRX Hedge Fund Activity: Q2 2023 in Review
28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2023, worth a combined $69.9M — up 244% from $20.3M a quarter earlier.
Fund positioning in TCRX was balanced in Q2 2023: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 4 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $14M. The largest seller was BlackRock, cutting an estimated $675K.
- 28 institutional investors held TScan Therapeutics (TCRX) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $69.9M of TScan Therapeutics stock for Q2 2023, up 244% quarter-over-quarter.
- 5 funds opened new TScan Therapeutics positions in Q2 2023 and 5 closed out, a net change of 0 holders.
- The largest TScan Therapeutics buyer in Q2 2023 was Lynx1 Capital Management, an estimated $14M added.
- The largest TScan Therapeutics seller in Q2 2023 was BlackRock, an estimated $675K sold.
Based on aggregated 13F filings for Q2 2023.